Creating Reference Gene Annotation for the Mouse C57BL6/J Genome Assembly
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Investigating the Role of the Ribonuclease DIS3 In
Investigating the role of the ribonuclease DIS3 in haematological cancers Sophie Rebecca Robinson A thesis submitted in partial fulfilment of the requirements of the University of Brighton and the University of Sussex for the degree of Doctor of Philosophy July 2016 Abstract Whole genome sequencing has recently identified DIS3 as a novel tumour suppressor gene in multiple myeloma. DIS3 is a conserved RNA exonuclease and catalytic subunit of the exosome, a protein complex involved in the 3’ to 5’ degradation and processing of messenger RNA and small RNAs. Messenger RNA processing and degradation is important in controlling gene expression and therefore cellular function, however the role DIS3 plays in the pathogenesis of haematological cancer remains unclear. Using RNAi as a means to knock-down DIS3, I have performed various functional assays to investigate the consequences of DIS3 loss-of function on myeloma cells. I have investigated cell viability, drug-sensitivity, mitotic errors, apoptosis and the generation of double-strand breaks in both transiently transfected myeloma cells and stable transfected adherent cells. I have also performed transcript profiling experiments in the form of RNA-sequencing to identify possible targets of DIS3 as well as synthetic lethality screens to identify proteins that may be cooperating with DIS3 mutations in myeloma pathogenesis. Overall, DIS3 knock-down did not appear to affect cellular phenotype in these assays, possibly indicating that DIS3 may be conferring a competitive advantage to cancer cells through a mechanism that only occurs in vivo. Alternatively, DIS3 mutations may not be driving tumourigenesis on their own but may either require another cellular pathway to be disrupted, or, may only be required to maintain the tumour rather than initiate it. -
Download.Soe
UC Santa Cruz UC Santa Cruz Previously Published Works Title The UCSC Genome Browser database: 2015 update. Permalink https://escholarship.org/uc/item/63r004hm Journal Nucleic acids research, 43(Database issue) ISSN 0305-1048 Authors Rosenbloom, Kate R Armstrong, Joel Barber, Galt P et al. Publication Date 2015 DOI 10.1093/nar/gku1177 Peer reviewed eScholarship.org Powered by the California Digital Library University of California D670–D681 Nucleic Acids Research, 2015, Vol. 43, Database issue Published online 26 November 2014 doi: 10.1093/nar/gku1177 The UCSC Genome Browser database: 2015 update Kate R. Rosenbloom1,*, Joel Armstrong1, Galt P. Barber1, Jonathan Casper1, Hiram Clawson1, Mark Diekhans1, Timothy R. Dreszer1, Pauline A. Fujita1, Luvina Guruvadoo1, Maximilian Haeussler1, Rachel A. Harte1, Steve Heitner1, Glenn Hickey1,AngieS.Hinrichs1, Robert Hubley2, Donna Karolchik1, Katrina Learned1, Brian T. Lee1,ChinH.Li1, Karen H. Miga1, Ngan Nguyen1, Benedict Paten1, Brian J. Raney1, Arian F. A. Smit2, Matthew L. Speir1, Ann S. Zweig1, David Haussler1,3, Robert M. Kuhn1 and W. James Kent1 1Center for Biomolecular Science and Engineering, CBSE, UC Santa Cruz, 1156 High Street, Santa Cruz, CA 95064, USA, 2Institute for Systems Biology, Seattle, WA 98109, USA and 3Howard Hughes Medical Institute, UCSC, Santa Cruz, CA 95064, USA Received September 18, 2014; Revised October 30, 2014; Accepted October 31, 2014 ABSTRACT Accompanying the genomes are details of the sequenc- ing and assembly, gene models from RefSeq (3,4), GEN- Launched in 2001 to showcase the draft human CODE (5), Ensembl (6,7) and UCSC (8), transcription ev- genome assembly, the UCSC Genome Browser idence from GenBank (9) and other sources, epigenetic database (http://genome.ucsc.edu) and associated and gene regulatory annotation including comprehensive tools continue to grow, providing a comprehensive data sets from the ENCODE project (10), comparative ge- resource of genome assemblies and annotations to nomics and evolutionary conservation annotation, repeti- scientists and students worldwide. -
DIS3 Isoforms Vary in Their Endoribonuclease Activity and Are Differentially Expressed Within Haematological Cancers
DIS3 isoforms vary in their endoribonuclease activity and are differentially expressed within haematological cancers Article (Published Version) Robinson, Sophie R, Viegas, Sandra C, Matos, Rute G, Domingues, Susana, Bedir, Marisa, Stewart, Helen J S, Chevassut, Timothy, Oliver, Antony W, Arraiano, Cecilia M and Newbury, Sarah F (2018) DIS3 isoforms vary in their endoribonuclease activity and are differentially expressed within haematological cancers. Biochemical Journal, 475 (12). pp. 2091-2105. ISSN 0264-6021 This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/46151/ This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher’s version. Please see the URL above for details on accessing the published version. Copyright and reuse: Sussex Research Online is a digital repository of the research output of the University. Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available. Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. -
DIS3 Isoforms Vary in Their Endoribonuclease Activity and Are Differentially Expressed Within Haematological Cancers
Biochemical Journal (2018) 475 2091–2105 https://doi.org/10.1042/BCJ20170962 Research Article DIS3 isoforms vary in their endoribonuclease activity and are differentially expressed within haematological cancers Sophie R. Robinson1, Sandra C. Viegas2, Rute G. Matos2, Susana Domingues2, Marisa Bedir3, Helen J.S. Stewart1, Timothy J. Chevassut1, Antony W. Oliver3, Cecilia M. Arraiano2 and Sarah F. Newbury1 1Medical Research Building, Brighton and Sussex Medical School, University of Sussex, Falmer, Brighton BN1 9PS, U.K.; 2Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av. da República, 2780-157 Oeiras, Portugal; 3School of Life Sciences, Genome Damage and Stability Centre, University of Sussex, Falmer, Brighton BN1 9RQ, U.K. Correspondence: Sarah F. Newbury ([email protected]) DIS3 (defective in sister chromatid joining) is the catalytic subunit of the exosome, a protein complex involved in the 30–50 degradation of RNAs. DIS3 is a highly conserved exoribonuclease, also known as Rrp44. Global sequencing studies have identified DIS3 as being mutated in a range of cancers, with a considerable incidence in multiple myeloma. In this work, we have identified two protein-coding isoforms of DIS3. Both isoforms are functionally relevant and result from alternative splicing. They differ from each other in the size of their N-terminal PIN (PilT N-terminal) domain, which has been shown to have endoribonuclease activity and tether DIS3 to the exosome. Isoform 1 encodes a full-length PIN domain, whereas the PIN domain of isoform 2 is shorter and is missing a segment with conserved amino acids. We have carried out biochemical activity assays on both isoforms of full-length DIS3 and the isolated PIN domains. -
Genome Annotation Standards Before the Data Deluge
Standards in Genomic Sciences (2011) 5:168-193 DOI:10.4056/sigs.2084864 Solving the Problem: Genome Annotation Standards before the data deluge William Klimke1, Claire O'Donovan2, Owen White3, J. Rodney Brister1, Karen Clark1, Boris Fedorov1, Ilene Mizrachi1, Kim D. Pruitt1, Tatiana Tatusova1 1The National Center for Biotechnology Information, National Library of Medicine, NIH, Building 45, Bethesda, MD 20894, USA 2UniProt, The EMBL Outstation, The European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, UK 3Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD 21201, USA The promise of genome sequencing was that the vast undiscovered country would be mapped out by comparison of the multitude of sequences available and would aid research- ers in deciphering the role of each gene in every organism. Researchers recognize that there is a need for high quality data. However, different annotation procedures, numerous databas- es, and a diminishing percentage of experimentally determined gene functions have resulted in a spectrum of annotation quality. NCBI in collaboration with sequencing centers, archival databases, and researchers, has developed the first international annotation standards, a fun- damental step in ensuring that high quality complete prokaryotic genomes are available as gold standard references. Highlights include the development of annotation assessment tools, community acceptance of protein naming standards, comparison of annotation resources to provide consistent annotation, and improved tracking of the evidence used to generate a par- ticular annotation. The development of a set of minimal standards, including the requirement for annotated complete prokaryotic genomes to contain a full set of ribosomal RNAs, transfer RNAs, and proteins encoding core conserved functions, is an historic milestone. -
Extensive Rewiring of Epithelial-Stromal Co-Expression Networks in Breast Cancer
Extensive rewiring of epithelial-stromal co-expression networks in breast cancer The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Oh, E., S. M. Christensen, S. Ghanta, J. C. Jeong, O. Bucur, B. Glass, L. Montaser-Kouhsari, et al. 2015. “Extensive rewiring of epithelial-stromal co-expression networks in breast cancer.” Genome Biology 16 (1): 128. doi:10.1186/s13059-015-0675-4. http:// dx.doi.org/10.1186/s13059-015-0675-4. Published Version doi:10.1186/s13059-015-0675-4 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:17295769 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Extensive rewiring of epithelial-stromal co-expression networks in breast cancer Oh et al. Oh et al. Genome Biology (2015) 16:128 DOI 10.1186/s13059-015-0675-4 Oh et al. Genome Biology (2015) 16:128 DOI 10.1186/s13059-015-0675-4 RESEARCH Open Access Extensive rewiring of epithelial-stromal co-expression networks in breast cancer Eun-Yeong Oh1,2,3†, Stephen M Christensen1,2,3†, Sindhu Ghanta1,2,3†, Jong Cheol Jeong1,2,3†, Octavian Bucur1,2,3, Benjamin Glass1,2,3, Laleh Montaser-Kouhsari1,2,3, Nicholas W Knoblauch1,2,3, Nicholas Bertos4, Sadiq MI Saleh4, Benjamin Haibe-Kains5,6, Morag Park4 and Andrew H Beck1,2,3* Abstract Background: Epithelial-stromal crosstalk plays a critical role in invasive breast cancer pathogenesis; however, little is known on a systems level about how epithelial-stromal interactions evolve during carcinogenesis. -
Based on Network Pharmacology and RNA Sequencing Techniques to Explore the Molecular Mechanism of Huatan Jiangzhuo Decoction for Treating Hyperlipidemia
Hindawi Evidence-Based Complementary and Alternative Medicine Volume 2021, Article ID 9863714, 16 pages https://doi.org/10.1155/2021/9863714 Research Article Based on Network Pharmacology and RNA Sequencing Techniques to Explore the Molecular Mechanism of Huatan Jiangzhuo Decoction for Treating Hyperlipidemia XiaowenZhou ,1 ZhenqianYan ,1 YaxinWang ,1 QiRen ,1 XiaoqiLiu ,2 GeFang ,3 Bin Wang ,4 and Xiantao Li 1 1Laboratory of TCM Syndrome Essence and Objectification, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, China 2Guangzhou Sagene Tech Co., Ltd., Guangzhou 510006, China 3College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, China 4Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518000, China Correspondence should be addressed to Xiantao Li; [email protected] Received 22 May 2020; Revised 12 March 2021; Accepted 18 March 2021; Published 12 April 2021 Academic Editor: Jianbo Wan Copyright © 2021 Xiaowen Zhou et al. +is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Hyperlipidemia, due to the practice of unhealthy lifestyles of modern people, has been a disturbance to a large portion of population worldwide. Recently, several scholars have turned their attention to Chinese medicine (CM) to seek out a lipid-lowering approach with high efficiency and low toxicity. +is study aimed to explore the mechanism of Huatan Jiangzhuo decoction (HTJZD, a prescription of CM) in the treatment of hyperlipidemia and to determine the major regulation pathways and potential key targets involved in the treatment process. -
Genenames.Org: the HGNC Resources in 2011 Ruth L
Nucleic Acids Research Advance Access published October 6, 2010 Nucleic Acids Research, 2010, 1–6 doi:10.1093/nar/gkq892 genenames.org: the HGNC resources in 2011 Ruth L. Seal*, Susan M. Gordon, Michael J. Lush, Mathew W. Wright and Elspeth A. Bruford European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, CB10 1SA, UK Received September 15, 2010; Accepted September 21, 2010 ABSTRACT In order to achieve this, we endeavour to contact the The HUGO Gene Nomenclature Committee (HGNC) researchers that work on particular genes for their Downloaded from aims to assign a unique gene symbol and name to advice and input before approving symbols, and encour- every human gene. The HGNC database currently age researchers to submit proposed gene symbols directly contains almost 30 000 approved gene symbols, to us to determine their suitability prior to publication. over 19 000 of which represent protein-coding The HGNC team attends conferences regularly to ensure that we are meeting the requirements of the community genes. The public website, www.genenames.org, and to discuss the nomenclature of specific gene families nar.oxfordjournals.org displays all approved nomenclature within Symbol and locus types. We work closely with the nomenclature Reports that contain data curated by HGNC editors committees for several other species, especially the mouse and links to related genomic, phenotypic and prote- (2), rat (3), zebrafish (4) and Xenopus (5) to ensure that omic information. Here we describe improvements orthologous vertebrate genes are assigned equivalent to our resources, including a new Quick Gene symbols wherever possible. HGNC symbols are used by Search, a new List Search, an integrated HGNC most biomedical databases, including Ensembl (6), Vega BioMart and a new Statistics and Downloads facility. -
Supplementary Information – Postema Et Al., the Genetics of Situs Inversus Totalis Without Primary Ciliary Dyskinesia
1 Supplementary information – Postema et al., The genetics of situs inversus totalis without primary ciliary dyskinesia Table of Contents: Supplementary Methods 2 Supplementary Results 5 Supplementary References 6 Supplementary Tables and Figures Table S1. Subject characteristics 9 Table S2. Inbreeding coefficients per subject 10 Figure S1. Multidimensional scaling to capture overall genomic diversity 11 among the 30 study samples Table S3. Significantly enriched gene-sets under a recessive mutation model 12 Table S4. Broader list of candidate genes, and the sources that led to their 13 inclusion Table S5. Potential recessive and X-linked mutations in the unsolved cases 15 Table S6. Potential mutations in the unsolved cases, dominant model 22 2 1.0 Supplementary Methods 1.1 Participants Fifteen people with radiologically documented SIT, including nine without PCD and six with Kartagener syndrome, and 15 healthy controls matched for age, sex, education and handedness, were recruited from Ghent University Hospital and Middelheim Hospital Antwerp. Details about the recruitment and selection procedure have been described elsewhere (1). Briefly, among the 15 people with radiologically documented SIT, those who had symptoms reminiscent of PCD, or who were formally diagnosed with PCD according to their medical record, were categorized as having Kartagener syndrome. Those who had no reported symptoms or formal diagnosis of PCD were assigned to the non-PCD SIT group. Handedness was assessed using the Edinburgh Handedness Inventory (EHI) (2). Tables 1 and S1 give overviews of the participants and their characteristics. Note that one non-PCD SIT subject reported being forced to switch from left- to right-handedness in childhood, in which case five out of nine of the non-PCD SIT cases are naturally left-handed (Table 1, Table S1). -
Supplementary Data
Supplemental figures Supplemental figure 1: Tumor sample selection. A total of 98 thymic tumor specimens were stored in Memorial Sloan-Kettering Cancer Center tumor banks during the study period. 64 cases corresponded to previously untreated tumors, which were resected upfront after diagnosis. Adjuvant treatment was delivered in 7 patients (radiotherapy in 4 cases, cyclophosphamide- doxorubicin-vincristine (CAV) chemotherapy in 3 cases). 34 tumors were resected after induction treatment, consisting of chemotherapy in 16 patients (cyclophosphamide-doxorubicin- cisplatin (CAP) in 11 cases, cisplatin-etoposide (PE) in 3 cases, cisplatin-etoposide-ifosfamide (VIP) in 1 case, and cisplatin-docetaxel in 1 case), in radiotherapy (45 Gy) in 1 patient, and in sequential chemoradiation (CAP followed by a 45 Gy-radiotherapy) in 1 patient. Among these 34 patients, 6 received adjuvant radiotherapy. 1 Supplemental Figure 2: Amino acid alignments of KIT H697 in the human protein and related orthologs, using (A) the Homologene database (exons 14 and 15), and (B) the UCSC Genome Browser database (exon 14). Residue H697 is highlighted with red boxes. Both alignments indicate that residue H697 is highly conserved. 2 Supplemental Figure 3: Direct comparison of the genomic profiles of thymic squamous cell carcinomas (n=7) and lung primary squamous cell carcinomas (n=6). (A) Unsupervised clustering analysis. Gains are indicated in red, and losses in green, by genomic position along the 22 chromosomes. (B) Genomic profiles and recurrent copy number alterations in thymic carcinomas and lung squamous cell carcinomas. Gains are indicated in red, and losses in blue. 3 Supplemental Methods Mutational profiling The exonic regions of interest (NCBI Human Genome Build 36.1) were broken into amplicons of 500 bp or less, and specific primers were designed using Primer 3 (on the World Wide Web for general users and for biologist programmers (see Supplemental Table 2) [1]. -
Transcriptome Analysis of Alternative Splicing-Coupled Nonsense-Mediated Mrna Decay in Human Cells Reveals Broad Regulatory Potential
bioRxiv preprint doi: https://doi.org/10.1101/2020.07.01.183327. this version posted July 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY 4.0 International license. Transcriptome analysis of alternative splicing-coupled nonsense-mediated mRNA decay in human cells reveals broad regulatory potential Courtney E. French1,#a*, Gang Wei2,#b*, James P. B. Lloyd2,3,#c, Zhiqiang Hu2, Angela N. Brooks1,#d, Steven E. Brenner1,2,3,$ 1 Department of Molecular and Cell Biology, University of California, Berkeley, CA, 94720, USA 2 Department of Plant and Microbial Biology, University of California, Berkeley, CA, 94720, USA 3 Center for RNA Systems Biology, University of California, Berkeley, CA, 94720, USA #a Current address: Department of Paediatrics, University of Cambridge, Cambridge, CB2 1TN, UK #b Current address: State Key Laboratory of Genetics Engineering & MOE Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, 200433, China #c Current address: ARC Centre of Excellence in Plant Energy Biology, University of Western Australia, Perth, Australia #d Current address: Department of Biomolecular Engineering, University of California, Santa Cruz, CA, USA * These authors contributed equally to this work $ Correspondence: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.07.01.183327. this version posted July 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY 4.0 International license. Abstract: To explore the regulatory potential of nonsense-mediated mRNA decay (NMD) coupled with alternative splicing, we globally surveyed the transcripts targeted by this pathway via RNA- Seq analysis of HeLa cells in which NMD had been inhibited. -
Ülevaade Põhimõtetest Ning Teise Põlvkonna Sekveneerimise Võimalike Artefaktsete Snvde Annoteerimine
TARTU ÜLIKOOL LOODUS- JA TÄPPISTEADUSTE VALDKOND MOLEKULAAR- JA RAKUBIOLOOGIA INSTITUUT BIOINFORMAATIKA ÕPPETOOL Anna Smertina Inimgenoomi ühenukleotiidiliste variatsioonide annotatsioon – ülevaade põhimõtetest ning teise põlvkonna sekveneerimise võimalike artefaktsete SNVde annoteerimine Bakalaureusetöö Maht: 12 EAP Juhendaja PhD Ulvi Gerst Talas TARTU 2016 Inimgenoomi ühenukleotiidiliste variatsioonide annotatsioon – ülevaade põhimõtetest ning teise põlvkonna sekveneerimise võimalike artefaktsete SNVde annoteerimine Teise põlvkonna sekveneerimine võimaldab tänu oma kiirusele ja suhtelisele odavusele järjestada kiiresti palju genoome, mille baasil on võimalik läbi viia nii ülegenoomseid assotsiatsiooniuuringuid kui ka kasutada andmeid kliinilises praktikas. Mõlemad lähenemised sõltuvad tugevalt SNVde ja teiste variatsioonide õigest tuvastamisest ning täpsest annotatsioonist. Antud töös tutvustatakse SNVde annoteerimise protsessi ja selle eripärasid, tuuakse välja annotatsiooni tõlgendamise erinevused lähtuvalt erinevatest tööriistadest ning andmebaasidest. Töö praktilises pooles näidatakse, et valepositiivselt tuvastatud SNVd võivad annoteerimise ja tulemuste tõlgendamise põhjal olla näiliselt füsioloogiliselt olulised. Artefaktsete SNVde tuvastamisega arvestamine võimaldab vältida vigaste andmete põhjal tehtud ekslikke järeldusi. Märksõnad: teise põlvkonna sekveneerimine, annoteerimine, SNV, bioinformaatika CERCS: B110 Bioinformaatika, meditsiiniinformaatika Annotation of single nucleotide variants in human genome: an overview and annotation